NCT04792021 is a Phase 3 clinical trial of N-acetylcysteine in Corona Virus Disease 19 (Covid19), sponsored by Ain Shams University.

Who is sponsoring NCT04792021?

NCT04792021 is sponsored by Ain Shams University.

What drugs are being tested in NCT04792021?

Interventions in NCT04792021: N-acetylcysteine.

What condition does NCT04792021 study?

NCT04792021 studies Corona Virus Disease 19 (Covid19), Corona Virus Infection, Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV2).

Is NCT04792021 still recruiting?

NCT04792021 is currently completed. Last updated 27 April 2022.

Last reviewed 2022-04-27 · How we verify

NCT04792021

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients

Completed Phase 3 Last updated 27 April 2022

What this trial tests

Phase 3 trial testing N-acetylcysteine in Corona Virus Disease 19 (Covid19) in 60 participants. Completed in 1 April 2022.

Timeline

9 March 2021

Primary endpoint
13 September 2021

1 April 2022

Quick facts

Lead sponsor	Ain Shams University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	9 March 2021
Primary completion	13 September 2021
Estimated completion	1 April 2022
Sites	1 location across Egypt

Drugs / interventions tested

N-acetylcysteine — full drug profile →

Conditions studied

Corona Virus Disease 19 (Covid19) — all drugs for Corona Virus Disease 19 (Covid19) →
Corona Virus Infection — all drugs for Corona Virus Infection →
Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV2) — all drugs for Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV2) →

Sponsor

Ain Shams University

Who can join

18 and older, any sex, with Corona Virus Disease 19 (Covid19) or Corona Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to assess the potential therapeutic effect of N-acetylcysteine "NAC" in COVID 19 patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895
Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19.
Li X, Zhang Z, Wang Z, Gutiérrez-Castrellón P, et al · · 2022 · cited 58× · PMID 35697684 · DOI 10.1038/s41392-022-01043-6
The role of cell death in SARS-CoV-2 infection.
Yuan C, Ma Z, Xie J, Li W, et al · · 2023 · cited 51× · PMID 37726282 · DOI 10.1038/s41392-023-01580-8
Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions.
Jiang Y, Zhao T, Zhou X, Xiang Y, et al · · 2022 · cited 44× · PMID 35923762 · DOI 10.1002/mco2.154
N-Acetylcysteine and Its Immunomodulatory Properties in Humans and Domesticated Animals.
Tieu S, Charchoglyan A, Paulsen L, Wagter-Lesperance LC, et al · · 2023 · cited 28× · PMID 37891946 · DOI 10.3390/antiox12101867
Molecular Mechanisms Related to Responses to Oxidative Stress and Antioxidative Therapies in COVID-19: A Systematic Review.
Tsermpini EE, Glamočlija U, Ulucan-Karnak F, Redenšek Trampuž S, et al · · 2022 · cited 27× · PMID 36009328 · DOI 10.3390/antiox11081609
Use of Thiols in the Treatment of COVID-19: Current Evidence.
Cazzola M, Rogliani P, Salvi SS, Ora J, et al · · 2021 · cited 20× · PMID 34448938 · DOI 10.1007/s00408-021-00465-3

Verify or expand the search:

Other trials of N-acetylcysteine

Trials testing the same drug.

NCT05074121 — NAC for Attenuation of COVID-19 Symptomatology · Phase 2 · unknown
NCT05494398 — Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label · Phase 2, PHASE3 · enrolling by invitation
NCT06236165 — Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of N-acetylcysteine Supplementation in Patients With · Phase 2 · completed
NCT05706402 — N-acetylcysteine (NAC) for the Treatment of Acute Exacerbation of COPD · Phase 3 · unknown
NCT00775476 — Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine · Phase 2 · recruiting

Other Ain Shams University trials

Trials by the same sponsor.

NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04792021 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
Last refreshed: 27 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04792021.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing